Safety and Feasibility Study of the Eddii Mobile Application

A Safety and Feasibility Study of the Eddii Mobile Application for Glucose Monitoring in Pediatric Patients With Type I Diabetes

The study is designed to measure the safety and feasibility of the Eddii mobile app for children living with Type-1 diabetes and using a CGM (Continuous Glucose monitor).

Study Overview

• Status: Completed
• Conditions: Type-1 Diabetes
• Intervention / Treatment: Behavioral: Eddii mobile application

Detailed Description

Wearable continuous glucose monitoring (CGM) sensors have revolutionized diabetes management over the past decade. By providing blood glucose (BG) concentration measurements continuously over consecutive days, CGMs are an increasingly adopted technology. While CGM devices have been shown to improve the safety and effectiveness of diabetes therapy to reduce hypoglycemia incidents and durability and to decrease glycemic variability CGM software and tools available for users to feel motivated and engaged are limited. Users of CGM often use an app that provides an interface for them to track their BG. In most cases, this app is offered by their CGM device provider.

These interfaces are considerably basic and scientific in nature, often developed by scientists and engineers for the everyday user. These apps are particularly dull and tiresome for children and adolescents living with diabetes. Current real-time CGM interfaces present real-time BG reading, in addition to the BG trend and a historical chart, together with minimal options for the user to enter lifestyle data such as medications, meals, and exercise. Examples of such default interfaces are ones offered by Dexcom, Medtronic Guardian and Freestyle Libre. While some of these apps provide patterns and health summaries to the user, these are provided in a separate app to the one streaming real-time BG. With the emergence of rtAPI (real-time Application Programming Interface) integrations with CGMs, there is ample opportunity to improve the dynamism, sophistication, and offerings within these CGM Apps , creating a platform that delights the user rather than one that makes diabetes management seem like a daily chore. Furthermore, it is hypothesized that creating additional engagement in the form of games and real-life rewards will improve glycemic control.

• Study Type: Interventional
• Enrollment (Actual): 92
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • New York
    • New York, New York, United States, 10016
      • Eddii, inc.

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 3 years to 10 years (Child)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria (Pediatric Volunteers)

Subject must meet all of the following to be enrolled.

• Volunteer, or their Authorized Representative, is willing and able to provide written informed consent, including authorization to release health information
• Volunteer is > 5 years and < 12 years of age (inclusive) at time of consent
• Volunteer has been diagnosed with Type 1 diabetes
• Volunteer has been utilizing the Dexcom continuous glucose monitor for a minimum of 6 months prior to enrollment in the study
• Volunteer must use the Dexcom mobile application
• Volunteer has a parent or legal guardian willing to participate in the study
• Volunteer must have access to and use an iOS smart phone, iPhone 10 model or above

Parent / Guardian Volunteers:

Subject must meet all of the following to be enrolled.

• Volunteer is willing and able to provide written informed consent, including authorization to release health information
• Volunteer has a child that meets study inclusion criteria and is willing to participate in the study
• Volunteer lives with a child that meets study inclusion criteria and is willing to participate in the study
• Volunteer is willing to be responsible for management of the Eddii mobile application use
• Volunteer must have and use an iOS smart phone device

Exclusion Criteria:

- EXCLUSION CRITERIA (Pediatric Volunteers)

Subject will be excluded if any of the below are present.

• Volunteer is unwilling or unable to provide written informed consent and/or does not have an authorized representative who can provide consent on their behalf
• Volunteer does not have access to an iOS smartphone device
• Volunteer does not have access to the internet
• Volunteer is enrolled in another research study at the time of enrollment

EXCLUSION CRITERIA (Parents / Guardians) Subject will be excluded if any of the below are present.

• Volunteer is unwilling or unable to provide written informed consent and/or does not have an authorized representative who can provide consent on their behalf
• Volunteer does not have access to an iOS smartphone device
• Volunteer does not have access to the internet
• Volunteer is enrolled in another research study at the time of enrollment

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Supportive Care
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
No Intervention: Control (Dexcom app); This group will use the Dexcom application for management of their blood glucose for the duration of the study (8 weeks).
Experimental: Intervention (Eddii app); This group will use the Dexcom application for the initial 2 weeks of the study, and switch to using the Eddii application on Day 14 of the study for the remaining 6 weeks of the study.	Behavioral: Eddii mobile application; Participants will use the Eddii mobile application in the intervention arm.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety of the Eddii App as assessed by accuracy and reliability of blood glucose measurements	Safety (Intervention Arm only) as assessed by: ○ Functionality and reliability of Eddii application by measuring reported faults	Eight Weeks
Feasibility of the Eddii App as measured by frequency of use	Feasibility (Intervention Arm only) as measured by: App analytics to determine total number and frequency of logins from enrollment to Week 8; App analytics to determine application features are easily accessible, understandable and are used effectively	Four Weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in glycaemic control measured as Time-in-Range (TIR) (70-180mg/dl)		Eight Weeks
QOL (Quality of Life) metrics	- QOL questionnaires conducted mid-study on weeks 2, 4, 6 and 8	Eight Weeks
User Engagement measured through app analytics	App-Specific Measures for Entirety of Study (Intervention Arm only) ○ Engagement and retention of users	Eight Weeks

Collaborators and Investigators

• Sponsor: Eddii, Inc.
• Investigators: Principal Investigator: Farhaneh Ahmadi, PhD, Eddii, inc.

Study record dates

Study Major Dates

• Study Start (Actual): January 2, 2021
• Primary Completion (Actual): July 31, 2022
• Study Completion (Actual): August 31, 2022

Study Registration Dates

• First Submitted: December 10, 2021
• First Submitted That Met QC Criteria: January 12, 2022
• First Posted (Actual): January 25, 2022

Study Record Updates

• Last Update Posted (Actual): October 5, 2022
• Last Update Submitted That Met QC Criteria: October 2, 2022
• Last Verified: October 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Glucose Metabolism Disorders; Metabolic Diseases; Immune System Diseases; Autoimmune Diseases; Endocrine System Diseases; Diabetes Mellitus; Diabetes Mellitus, Type 1
• Other Study ID Numbers: LeafStudy

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No